Long-term effect of interferon therapy in chronic hepatitis B.

[1]  J. Bartolomé,et al.  Persistence of hepatitis B virus DNA after reduction of viral replication in serum and liver , 1992, Journal of medical virology.

[2]  M. Mearns,et al.  Hepatitis B virus DNA in peripheral‐blood mononuclear cells in chronic hepatitis B after HBsAg clearance , 1992, Hepatology.

[3]  S. Günther,et al.  Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. , 1992, Virology.

[4]  H. Will,et al.  Precore mutant hepatitis B virus infection and liver disease. , 1992, Gastroenterology.

[5]  M. Loriot,et al.  Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti‐HBe or HBsAg to Anti‐HBs seroconversion in patients with chronic hepatitis B , 1992, Hepatology.

[6]  J. Bartolomé,et al.  Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. , 1992, Journal of hepatology.

[7]  A. Lok,et al.  Precore sequence variation in Chinese isolates of hepatitis B virus. , 1992, The Journal of infectious diseases.

[8]  T. Ishikawa,et al.  Detection of pre-C and core region mutants of hepatitis B virus in chronic hepatitis B virus carriers. , 1991, The Journal of clinical investigation.

[9]  E. Brunt,et al.  Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen. , 1991, Annals of internal medicine.

[10]  O. Yokosuka,et al.  Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. , 1991, The New England journal of medicine.

[11]  J. Wands,et al.  A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. , 1991, The New England journal of medicine.

[12]  H. Will,et al.  Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Hoofnagle,et al.  Long-term remission of chronic hepatitis B after alpha-interferon therapy. , 1991, Annals of internal medicine.

[14]  A. von Brunn,et al.  Antibodies in Anti‐HBe—positive patient sera bind to an HBe protein expressed on the cell surface of human hepatoma cells: Implications for virus clearance , 1991, Hepatology.

[15]  V. Carreño,et al.  Detection of HBeAg/anti-HBe immune complexes in the reactivation of hepatitis B virus replication among anti-HBe chronic carriers. , 2008, Liver.

[16]  V. Carreño,et al.  Hepatitis B virus DNA in liver and peripheral blood mononuclear cells during reduction in virus replication. , 1990, Gastroenterology.

[17]  H. Okamoto,et al.  Defects in the precore region of the HBV genome in patients with chronic hepatitis B after sustained seroconversion from HBeAg to anti‐HBe induced spontaneously or with interferon therapy , 1990, Hepatology.

[18]  R. Purcell,et al.  Evidence against a requisite role for defective virus in the establishment of persistent hepadnavirus infections. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Will,et al.  Latency and reactivation of a precore mutant hepatitis B virus in a chronically infected patient. , 1990, Journal of hepatology.

[20]  H. Okamoto,et al.  Chronic active hepatitis with hepatitis B virus DNA and antibody against e antigen in the serum. Disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region. , 1990, Gastroenterology.

[21]  P. Marcellin,et al.  Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B , 1990, Hepatology.

[22]  A. Zuckerman,et al.  Vaccine-induced escape mutant of hepatitis B virus , 1990, The Lancet.

[23]  E. Schiff,et al.  A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B , 1990 .

[24]  J. Wands,et al.  Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers , 1990, Hepatology.

[25]  E. Tanzi,et al.  High genomic variability in the pre‐C region of hepatitis B virus in anti‐HBe, HBV DNA‐positive chronic hepatitis , 1990, Journal of medical virology.

[26]  J. Bartolomé,et al.  Hepatitis B virus DNA patterns in the liver of children with chronic hepatitis B , 1990, Journal of medical virology.

[27]  R. Tur-kaspa,et al.  Corticosteroids stimulate hepatitis B virus DNA, mRNA and protein production in a stable expression system. , 1990, Journal of hepatology.

[28]  C. Trépo,et al.  Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. , 1990, Virology.

[29]  H. Will,et al.  A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. , 1990, Journal of hepatology.

[30]  F Tsuda,et al.  Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen , 1990, Journal of virology.

[31]  M. Loriot,et al.  Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy. , 1990, Annals of internal medicine.

[32]  H. Thomas,et al.  The hepatitis B virus and the host response. , 1990, Journal of hepatology.

[33]  H. Schlicht,et al.  The secretory core protein of human hepatitis B virus is expressed on the cell surface , 1989, Journal of virology.

[34]  G. Fattovich,et al.  Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B. , 1989, Journal of hepatology.

[35]  R. Perrillo.  Treatment of Chronic Hepatitis B with Interferon: Experience in Western Countries , 1989, Seminars in liver disease.

[36]  H. Thomas,et al.  MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1989, The Lancet.

[37]  G. Gasbarrini,et al.  A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy , 1989, Hepatology.

[38]  M. Brunetto,et al.  Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen , 1989, Hepatology.

[39]  J. Miyazaki,et al.  Demethylation by 5‐Azacytidine Results in the Expression of Hepatitis B Virus Surface Antigen in Transgenic Mice , 1989, Japanese journal of cancer research : Gann.

[40]  R. Purcell,et al.  Complete nucleotide sequence of a molecular clone of woodchuck hepatitis virus that is infectious in the natural host. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Brunetto.  Identification of HBV variants which cannot produce pre-core derived HBeAg and may be responsible for severe hepatitis , 1989 .

[42]  H. Blum,et al.  The molecular biology of hepatitis B virus. , 1989, Trends in genetics : TIG.

[43]  C. Bréchot,et al.  TRANSMISSION OF HEPATITIS B FROM HEPATITIS-B-SERONEGATIVE SUBJECTS , 1988, The Lancet.

[44]  R. Fukuda,et al.  Alteration of infection pattern of duck hepatitis B virus by immunomodulatory drugs , 1988, Journal of medical virology.

[45]  R. Tedder,et al.  Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. , 1988, AIDS.

[46]  S. Ramón y. Cajal,et al.  Different doses of recombinant alpha interferon in the treatment of chronic hepatitis B patients without antibodies against the human immunodeficiency virus. , 1988, Hepato-gastroenterology.

[47]  L. Poellinger,et al.  The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. , 1988, Virology.

[48]  J. Hoofnagle,et al.  Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B , 1988 .

[49]  M. Peters,et al.  Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. , 1988, Annals of internal medicine.

[50]  R. Purcell,et al.  Sequence comparison of woodchuck hepatitis virus replicative forms shows conservation of the genome. , 1988, Virology.

[51]  S. Ramón y. Cajal,et al.  A controlled study of treatment with recombinant interferon alpha in chronic hepatitis B virus infection: induction and maintenance schedules. , 1987, Antiviral research.

[52]  H. Okamoto,et al.  Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. , 1987, The Japanese journal of experimental medicine.

[53]  Heather M. Smith,et al.  Loss of HBsAg with interferon‐α therapy in chronic hepatitis D virus infection , 1993, Journal of medical virology.

[54]  C. Babinet,et al.  Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[55]  J. Bartolomé,et al.  Changes of hepatitis B virus (HBV) markers during prolonged recombinant interferon alpha-2A treatment of chronic HBV infection. , 1987, Journal of hepatology.

[56]  H. Varmus,et al.  The molecular biology of the hepatitis B viruses. , 1987, Annual review of biochemistry.

[57]  S. Iwarson,et al.  Cytotoxic T-cell responses to the nucleocapsid proteins of HBV in chronic hepatitis. Evidence that antibody modulation may cause protracted infection. , 1987, Journal of hepatology.

[58]  P. Karayiannis,et al.  Lymphoblastoid interferon therapy of chronic HBV infection. A comparison of 12 vs. 24 weeks of thrice weekly treatment. , 1987, Journal of hepatology.

[59]  J. Melnick,et al.  Hepatitis B virus DNA in mononuclear cells and analysis of cell subsets for the presence of replicative intermediates of viral DNA. , 1986, The Journal of infectious diseases.

[60]  C. Babinet,et al.  Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice. , 1985, Science.

[61]  J. Hoofnagle,et al.  Spontaneous reactivation of chronic hepatitis B virus infection. , 1984, Gastroenterology.

[62]  T. Merigan,et al.  Acute Dane particle suppression with recombinant leukocyte A interferon in chronic hepatitis B virus infection. , 1983, The Journal of infectious diseases.

[63]  M. Balasegaram,et al.  Hepatitis B virus DNA in liver and white blood cells of patients with hepatoma. , 1983, DNA.

[64]  J. Hoofnagle,et al.  Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. , 1982, Annals of internal medicine.

[65]  C. Lightdale,et al.  Primary hepatocellular carcinoma with hepatitis B antigenemiA: Effects of chemotherapy , 1980, Cancer.

[66]  Christine Pourcel,et al.  Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma , 1980, Nature.

[67]  Y. Cossart,et al.  REACTIVATION OF HEPATITIS B AFTER TRANSPLANTATION OPERATIONS , 1977, The Lancet.

[68]  J. Wands,et al.  Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. , 1975, Gastroenterology.